All In Biotech

Drug Trial Radar · NCT03921060

Markers of Osteoporosis in Cystic Fibrosis

Last checked: Nov 20, 2026Latest source record: May 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Sep 2, 2021

Primary completion

Jul 2027

Study completion Jul 2027

Sponsor

Lead sponsor
University of Texas Southwestern Medical CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Apr 19, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Sequential
Masking
Triple (participant, care provider, investigator)
Primary purpose
Diagnostic
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 64 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Main Study Up to 100 subjects, both non-CF volunteers and Cystic Fibrosis (CF) patients, will participate in a single study visit that will include a DEXA scan, micro CT, and blood collection. Denosumab (Prolia) Sub study Approximately 10 adult subjects with CF who participated in the main study and have results indicating bone disease will receive treatment with Denosumab for up to 5 years. They will be asked to return for repeat DEXA scans, micro CT, blood collection, and documenting of any adverse events.

Conditions

  • Cystic Fibrosis

Interventions

  • DenosumabDrug

    treatment with denosumab every 6 months for up to 5 years

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. DEXA resultsTime frame: Looking at single timepoints and well as changes for up to 5 years for those in the sub-study
  2. Micro CT resultsTime frame: Looking at single timepoints and well as changes for up to 5 years for those in the sub-study

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • UT Southwestern Medical Center

    Dallas, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.